

EU-RESPONSE Lab Network Newsletter



December 2023#2


« The investigators of the DisCoVeRy trial would like to congratulate the birth and development of the EU-RESPONSE lab network ! We recognize the great importance of this network, as it is indeed difficult to carry out multicenter, international, clinical trials on viral respiratory pathogens without such a network ! As the EU-RESPONSE project continues to evolve, we are looking forward to future close collaboration with you ! »

DISCOVERY

Maya Hites and Florence Ader, Discovery main investigators

External Quality Assessment

A panel of spiked samples has been quantified with the COVID-19 R-GENE[®] kit and the QUANTI SARS-CoV-2 R-GENE [®] IUO range developed to respond to this European study. Each lab worked with its own molecular platform and normalized viral loads were compared to CNR – Lyon Lab results.



Some variabilities have been observed according to the nucleic acid extraction methods. The extraction efficiency significantly influences the yield of RNA leading to variations in PCR SARS-CoV-2 Ct values but not the yield of cellular DNA that is comparable between extraction platforms.

Next year we will focus on new solutions to take into account RNA extraction yield variabilities in quantification. Encouraging preliminary results have been already obtained.

A great action of preparedness for a new viral pandemic to evaluate new drugs !

"I'm delighted to participate in this network of laboratories to provide a standardized quantitative SARS-CoV-2 RT-PCR test. A quantitative assay is essential to evaluate the effectiveness of treatments and standardized test(s) across laboratories would enable rapid and robust evaluation on sites, avoiding timeconsuming centralization of sample testing."



Karen Brengel-Pesce, bioMérieux, R&D molecular Biology

SAVE THE DATE

Next Working Group ! Consortium Meeting in Madrid 19-20/06/2024

Last Discovery publication

"Cardiac Adverse Events and Remdesivir in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial" - postprint

Clinical Infectious Diseases

Next steps

Switzerland soon part of our network !

Development of the network to other European countries



https://eu-response.eu/virology-network/



The EU-RESPONSE project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101015736. However the contents of this newsletter do not necessarily reflect the position or opinion of the European Commission.